Tag: FDA

masimo root
Product News

Masimo Receives FDA Clearance of Continuous RRp Monitoring

Masimo announced that continuous RRp® (respiration rate from the photoplethysmograph) monitoring of adult and pediatric patients with Rad-97®, Radical-7®, and Radius-7® Pulse CO-Oximeters® has received FDA clearance. With this clearance, both continuous and spot-check RRp are now available in the US, supported in a variety of pulse oximetry sensors and configurations, including the […]

banned
Respiratory

Michigan Governor Bans All Flavored Vaping Products

The American Thoracic Society applauds Michigan Governor Gretchen Whitmer’s decision to ban the sale of all flavored e-cigarette and vaping products in the state of Michigan. Governor Whitmer’s decision is an appropriate response to the 215 recently reported cases of e-cigarette triggered acute illnesses that have resulted in hospitalization and in at […]

fda warning for sleep meds
Pharmacological

Black Box Warning Added to Common Sleep Meds

The Food and Drug Administration (FDA) is advising that rare but serious injuries have happened with certain common prescription insomnia medicines because of sleep behaviors, including sleepwalking, sleep driving, and engaging in other activities while not fully awake. These complex sleep behaviors have also resulted in deaths. These behaviors appear […]

orkambi for cystic fibrosis
Pediatric Health Pharmacological Sleep Disorders

FDA Approves ORKAMBI®, First Medicine to Treat the Underlying Cause of CF for Children Ages 2-5 Years with Most Common Form of the Disease

Vertex Pharmaceuticals Incorporated announced the U.S. Food and Drug Administration (FDA) has approved ORKAMBI® (lumacaftor/ivacaftor) to include use in children ages 2 through 5 years with cystic fibrosis (CF) who have two copies of the F508del-CFTR mutation, making it the first medicine approved to treat the underlying cause of CF […]